Product logins

Find logins to all Clarivate products below.


Interventional Cardiology Devices | Eastern Europe | 2017 | Market Analysis

The Eastern European market for IC devices will expand modestly through 2025; although an expanding CAD patient pool and increasing adoption of premium-priced devices—such as BVSDCBs, and intravascular imaging cathethers and FFR guidewires—will support revenues, continuing budgetary constraints among Eastern European facilities, particularly in Romania and Russia, will inhibit uptake of expensive products and limit overall market growth.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional cardiology devices in Czech Republic, Hungary, Poland, Romania, and Russia across a 10-year period.

Related Medtech Insights Reports

Report
Large-Joint Reconstructive Implants – Market Insights – Europe (Supplemental)
The European large-joint reconstructive implant market is poised for long-term growth, driven by the adoption of innovative technologies such as 3-D printed implants and smart implants, as well as…
Report
Neurovascular Devices – Market Insights – Europe
The European neurovascular device market is poised to experience strong growth through 2034. This growth will be driven by the introduction of newly developed technologies, increasing adoption of…
Report
Interventional Cardiology Devices – Market Insights – Europe
The European interventional cardiology device market is highly competitive and poised for growth, driven by increasing PCI volumes for complex CAD cases and the adoption of innovative devices and…
Report
Interventional Cardiology Devices – Market Insights – Latin America
The Latin American IC device market will see strong growth over the forecast period, driven by a rising patient population, the introduction of next-generation devices, and the expanding adoption…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2034, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…